Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Leukemia

Volumn 28, Issue 11, 2014, Pages 2251-2254

  Pierceall, W E ^a   Warner, S L ^b   Lena, R J ^a   Doykan, C ^a   Blake, N ^a   Elashoff, M ^a   Hoff, D V ^b,c   Bearss, D J ^b   Cardone, M H ^a   Andritsos, L ^d   Byrd, J C ^d   Lanasa, M C ^e   Grever, M R ^d   Johnson, A J ^d  

^a Eutropics Pharmaceuticals   (United States)

^b Tolero Pharmaceuticals Inc ^*  (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; FLAVONOID; FLAVOPIRIDOL; PIPERIDINE DERIVATIVE; PROTEIN BCL X;

ADULT; AGED; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOCHONDRION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOCHONDRIA; PIPERIDINES;

EID: 84922332702     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.206     Document Type: Letter

References (15)

1. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29: 1253–1257. DOI: 10.1016/j.leukres.2005.03.010
2. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11: 4176–4181. DOI: 10.1158/1078-0432.CCR-04-2276
3. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012–6018. DOI: 10.1200/JCO.2009.22.6944
4. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399–404. DOI: 10.1182/blood-2006-05-020735
5. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ et al. Flavopiridol treatment of patients aged 70 or older with refractory or relapsedchronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 2012; 97: 423–427. DOI: 10.3324/haematol.2011.047324
6. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637–2645. DOI: 10.1182/blood-2008-07-168583
7. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129–1133. DOI: 10.1126/science.1206727
8. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R et al. BH3 profiling discriminates response to Cytarabine-based treatment of acute myeloid leukemia. Mol Cancer Ther 2013; 12: 2940–2949. DOI: 10.1158/1535-7163.MCT-13-0692
9. Chen S, Dai Y, Pei X-Y, Myers J, Wang L, Kramer LB et al. CDK inhibitors up-regulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 2012; 72: 4225–4237. DOI: 10.1158/0008-5472.CAN-12-1118
10. Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jone JA et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia 2012; 26: 1442–1444. DOI: 10.1038/leu.2011.375
11. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804–3816.
12. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000; 343: 1910–1916. DOI: 10.1056/NEJM200012283432602
13. AbdelSalam M, El Sissy A, Samra MA, Ibrahim S, El-Markaby D, Gadallah F. The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia. Hematology 2008; 13: 147–153. DOI: 10.1179/102453308X316121
14. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329–331. DOI: 10.1182/blood-2011-10-386144
15. Willander K, Dutta RK, Ungerback J, Gunnarsson R, Juliusson G, Fredrikson M et al. NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. BMC Cancer 2013; 13: 274. DOI: 10.1186/1471-2407-13-274